What Has Driven The Outperformance Of GlaxoSmithKline In 2016 And Why It's Likely To Continue In 2017 Seeking Alpha, 09 Jan 2017 In spite of being the best-performing EU Pharma in 2016, GlaxoSmithKline (NYSE: GSK ) is still attractively valued, trading at…